CytomX Therapeutics, Inc.

CytomX Therapeutics is an oncology-focused biopharmaceutical company that develops potent biologics designed to treat the tumor microenvironment. Its core technology is the PROBODY platform, which creates conditionally activated therapeutics that remain inactive until they reach the tumor site, potentially improving safety and efficacy. The company's pipeline includes CX-904, a T-cell engaging bispecific antibody targeting EGFR on tumor cells and CD3 on T cells; CX-2051, a conditionally activated antibody-drug conjugate (ADC) for EpCAM-expressing epithelial cancers like colorectal cancer; and CX-801, an interferon alpha-2b PROBODY cytokine. Additionally, it is developing CX-2029, a conditional activated ADC targeting CD71, and BMS-986288, a PROBODY version of non-fucosylated ipilimumab. CytomX also has strategic collaborations with Amgen, Astellas, Bristol Myers Squibb, Regeneron, and Moderna, and a clinical trial collaboration with Merck for evaluating CX-801 in combination with KEYTRUDA (pembrolizumab).

CytomX Therapeutics is listed on the Nasdaq Global Select Market (NasdaqGS) under the ticker symbol CTMX. Its shares are traded in US dollars (USD), as the company is based in the United States. The exchange is one of the major US stock exchanges, providing liquidity and visibility for investors. The listing on NasdaqGS indicates that the company meets stringent financial and governance standards. Investors can trade CTMX shares during regular US market hours, and the stock is accessible through most brokerage platforms that offer US equities.

CytomX Therapeutics operates in the Healthcare sector, specifically within the Biotechnology industry. As a biotechnology company, it focuses on research and development of novel biologic therapies, particularly for oncology. The biotechnology industry involves using living organisms or their components to develop drugs and diagnostic tools. CytomX's work centers on creating conditionally activated biologics that target the tumor microenvironment, aiming to improve therapeutic outcomes for cancer patients. This places it among other biotech firms that specialize in immuno-oncology and antibody-based therapies.

CytomX Therapeutics is headquartered in South San Francisco, California, United States. The company was founded in 2008. South San Francisco is a major hub for biotechnology and life sciences, often referred to as the 'Biotech Bay,' providing access to a skilled workforce and research collaborations. The company's location in this cluster supports its focus on oncology biologics R&D. Since its founding, CytomX has built a pipeline of conditionally activated therapeutics and established partnerships with several large pharmaceutical companies, including Amgen, Astellas, Bristol Myers Squibb, Regeneron, and Moderna.

CytomX Therapeutics' pipeline includes several key product candidates. CX-904 is a T-cell engaging bispecific antibody targeting EGFR on tumor cells and CD3 on T cells, designed for solid tumors. CX-2051 is a conditionally activated ADC targeting EpCAM for epithelial cancers such as colorectal cancer. CX-801 is an interferon alpha-2b PROBODY cytokine. Additionally, CX-2029 is a conditional activated ADC targeting CD71, and BMS-986288 is a PROBODY version of non-fucosylated ipilimumab. The company has strategic collaborations with Amgen, Astellas, Bristol Myers Squibb, Regeneron, and Moderna to advance these programs. It also has a clinical trial collaboration and supply agreement with Merck to evaluate CX-801 in combination with KEYTRUDA (pembrolizumab), an anti-PD-1 therapy.